Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1598-1603
doi: 10.1161/hq1001.097065
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iglarz, M.
Right arrow Articles by Lévy, B. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iglarz, M.
Right arrow Articles by Lévy, B. I.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*NITRIC OXIDE
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Angiogenesis
Right arrow Other Vascular biology
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:1598.)
© 2001 American Heart Association, Inc.


Vascular Biology

Chronic Blockade of Endothelin Receptors Improves Ischemia-Induced Angiogenesis in Rat Hindlimbs Through Activation of Vascular Endothelial Growth Factor–NO Pathway

Marc Iglarz; Jean-Sébastien Silvestre; Micheline Duriez; Daniel Henrion; Bernard I. Lévy

From the Institut National de la Santé et de la Recherche Médicale U541, IFR Circulation-Lariboisière, Université Paris VII, and the Department of Physiology (B.I.L.), AP-HP Hôpital Lariboisière, Paris, France.

Reprint requests to Daniel Henrion, PhD, INSERM U541, 41 Bd de la Chapelle, Hôpital Lariboisière, 75475 Paris cedex 10, France. E-mail daniel.henrion{at}inserm.lrb.ap-hop-paris.fr

Abstract— This study investigated in vivo the putative angiogenic role of endothelin (ET)-1 in a model of ischemia-induced angiogenesis. Ischemia was produced by unilateral femoral artery occlusion in Wistar rats submitted to either chronic ET-1 infusion (2 nmol · kg-1 · min-1) or to a dual ETA/ETB receptor antagonist (bosentan, 100 mg · kg-1 · d-1) for 3 and 28 days. Arterial density was evaluated by microangiography and measurement of capillary and arteriolar density in hindlimb muscles. ET-1 infusion had no effect on ischemia-induced angiogenesis and was associated with a slight decrease in vascular endothelial growth factor (VEGF) content measured by Western blot analysis. Conversely, bosentan induced a marked increase in vessel density at 3 and 28 days (1.4-fold and 1.7-fold, respectively, compared with no treatment; P<0.05), which was associated with an increase in VEGF and endothelial NO synthase levels in ischemic legs (by 31±8% and 45±23%, respectively, at 3 days and by 65±13% and 55±15%, respectively, at 28 days; P<0.05 versus nontreated rats). At day 28, the proangiogenic effect of bosentan was abolished when NO synthesis inhibitor NG-nitro-L-arginine methyl ester (10 mg · kg-1 · d-1) or VEGF-neutralizing antibody (2.5 µg/kg twice a week) were coadministered with bosentan. Those results provide the first evidence of an early and sustained proangiogenic effect of endothelin antagonism associated with an upregulation of VEGF and endothelial NO synthase in vivo.


Key Words: endothelin-1 • angiogenesis • vascular endothelial growth factor • nitric oxide • ischemia




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
K. T. B. Mouchaers, I. Schalij, A. M. G. Versteilen, A. M. Hadi, G. P. van Nieuw Amerongen, V. W. M. van Hinsbergh, P. E. Postmus, W. J. van der Laarse, and A. Vonk-Noordegraaf
Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H200 - H207.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
E. I. Ager, J. Neo, and C. Christophi
The renin-angiotensin system and malignancy
Carcinogenesis, September 1, 2008; 29(9): 1675 - 1684.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. Jesmin, S. Zaedi, N. Shimojo, M. Iemitsu, K. Masuzawa, N. Yamaguchi, C. N. Mowa, S. Maeda, Y. Hattori, and T. Miyauchi
Endothelin antagonism normalizes VEGF signaling and cardiac function in STZ-induced diabetic rat hearts
Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E1030 - E1040.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
Z. W. Zhuang, L. Gao, M. Murakami, J. D. Pearlman, T. J. Sackett, M. Simons, and E. D. de Muinck
Arteriogenesis: Noninvasive Quantification with Multi-Detector Row CT Angiography and Three-dimensional Volume Rendering in Rodents
Radiology, September 1, 2006; 240(3): 698 - 707.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
T. Carpenter, S. Schomberg, W. Steudel, J. Ozimek, K. Colvin, K. Stenmark, and D. D. Ivy
Endothelin B Receptor Deficiency Predisposes to Pulmonary Edema Formation via Increased Lung Vascular Endothelial Cell Growth Factor Expression
Circ. Res., September 5, 2003; 93(5): 456 - 463.
[Abstract] [Full Text] [PDF]